JP2022508953A - Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 - Google Patents

Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 Download PDF

Info

Publication number
JP2022508953A
JP2022508953A JP2021547054A JP2021547054A JP2022508953A JP 2022508953 A JP2022508953 A JP 2022508953A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2021547054 A JP2021547054 A JP 2021547054A JP 2022508953 A JP2022508953 A JP 2022508953A
Authority
JP
Japan
Prior art keywords
methyl
mmol
pyrazole
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508953A5 (cg-RX-API-DMAC10.html
Inventor
サイモン ニコラス ハイダー,
レピン リ,
マーク ジー. ブレシュ,
ローパ ライ,
リン バネン,
マイケル ウォーカー,
Original Assignee
アッセンブリー バイオサイエンシズ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッセンブリー バイオサイエンシズ,インコーポレイテッド filed Critical アッセンブリー バイオサイエンシズ,インコーポレイテッド
Publication of JP2022508953A publication Critical patent/JP2022508953A/ja
Publication of JP2022508953A5 publication Critical patent/JP2022508953A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021547054A 2018-10-22 2019-10-22 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物 Pending JP2022508953A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862748906P 2018-10-22 2018-10-22
US62/748,906 2018-10-22
US201962858790P 2019-06-07 2019-06-07
US62/858,790 2019-06-07
PCT/US2019/057362 WO2020086533A1 (en) 2018-10-22 2019-10-22 5-membered heteroaryl carboxamide compounds for treatment of hbv

Publications (2)

Publication Number Publication Date
JP2022508953A true JP2022508953A (ja) 2022-01-19
JP2022508953A5 JP2022508953A5 (cg-RX-API-DMAC10.html) 2023-06-22

Family

ID=68610300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547054A Pending JP2022508953A (ja) 2018-10-22 2019-10-22 Hbvの処置のための5員のヘテロアリールカルボキサミド化合物

Country Status (15)

Country Link
US (2) US11560370B1 (cg-RX-API-DMAC10.html)
EP (1) EP3870296A1 (cg-RX-API-DMAC10.html)
JP (1) JP2022508953A (cg-RX-API-DMAC10.html)
KR (1) KR20210095143A (cg-RX-API-DMAC10.html)
CN (1) CN113195055A (cg-RX-API-DMAC10.html)
AU (1) AU2019364352A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021007602A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117449A1 (cg-RX-API-DMAC10.html)
IL (1) IL282433A (cg-RX-API-DMAC10.html)
MA (1) MA53983A (cg-RX-API-DMAC10.html)
MX (1) MX2021004580A (cg-RX-API-DMAC10.html)
PH (1) PH12021550887A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202104086PA (cg-RX-API-DMAC10.html)
TW (1) TW202028190A (cg-RX-API-DMAC10.html)
WO (1) WO2020086533A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523241A (ja) * 2020-04-22 2023-06-02 アッセンブリー バイオサイエンシズ,インコーポレイテッド Hbvの処置のための5員のヘテロアリールカルボキサミド化合物
JP2024539504A (ja) * 2021-10-20 2024-10-28 アセンブリー・バイオサイエンシーズ・インコーポレイテッド プロセス

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205264A (zh) * 2020-02-25 2020-05-29 成都睿智化学研究有限公司 一种合成同位羟基和甲磺酰甲基化合物的新方法
US20230295096A1 (en) * 2020-04-22 2023-09-21 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
JP2023551474A (ja) * 2020-11-25 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置および予防のための芳香族架橋環アミド誘導体
JP2024541124A (ja) * 2021-10-20 2024-11-06 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規結晶形態
WO2023069547A1 (en) * 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023105481A1 (en) * 2021-12-10 2023-06-15 Assembly Biosciences, Inc. Pharmaceutical compositions for the treatment of hbv
WO2024173196A1 (en) * 2023-02-17 2024-08-22 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
KR102827002B1 (ko) * 2023-06-28 2025-06-30 국립순천대학교산학협력단 신규한 마리노바자난 화합물 및 이를 포함하는 암 전이 및 침윤 억제, 또는 암 치료용 조성물
WO2025029961A1 (en) * 2023-07-31 2025-02-06 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof
WO2025087274A1 (zh) 2023-10-27 2025-05-01 浙江海正药业股份有限公司 氮杂双环类衍生物及其制备方法和用途
CN117603089A (zh) * 2023-11-29 2024-02-27 南通瑞合达医药科技有限公司 一种环戊腈的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
JP2006510627A (ja) * 2002-12-05 2006-03-30 ヴァーナリス(ケンブリッジ)リミテッド 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体
JP2012526820A (ja) * 2009-05-12 2012-11-01 ロマーク ラボラトリーズ エル.シー. ハロアルキルヘテロアリールベンズアミド化合物
CN105503730A (zh) * 2015-12-25 2016-04-20 山东大学 吡唑类衍生物及其制备方法与应用
JP2016518437A (ja) * 2013-05-17 2016-06-23 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
CN108250112A (zh) * 2018-01-30 2018-07-06 西北大学 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008130584A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
WO2013006394A1 (en) 2011-07-01 2013-01-10 Institute For Hepatitis And Virus Research Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US9968650B2 (en) 2011-07-13 2018-05-15 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
AR089671A1 (es) 2012-01-06 2014-09-10 Janssen R & D Ireland 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
NZ704758A (en) 2012-08-28 2018-06-29 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
HK1215030A1 (zh) 2012-11-09 2016-08-12 Indiana University Research And Technology Corporation 用於hbv組裝效應劑的替代用途
CN104918612B (zh) 2012-12-06 2019-10-25 巴鲁克斯布隆伯格研究所 作为抗hbv感染的抗病毒剂的官能化苯甲酰胺衍生物
HK1217649A1 (zh) 2012-12-27 2017-01-20 德雷克塞尔大学 針對hbv感染的新型抗病毒劑
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途
PE20151951A1 (es) 2013-05-17 2015-12-26 Hoffmann La Roche Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CA2928003A1 (en) * 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
EP3271019A1 (en) * 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
UY37581A (es) * 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
JP2006510627A (ja) * 2002-12-05 2006-03-30 ヴァーナリス(ケンブリッジ)リミテッド 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体
JP2012526820A (ja) * 2009-05-12 2012-11-01 ロマーク ラボラトリーズ エル.シー. ハロアルキルヘテロアリールベンズアミド化合物
JP2016518437A (ja) * 2013-05-17 2016-06-23 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
CN105503730A (zh) * 2015-12-25 2016-04-20 山东大学 吡唑类衍生物及其制备方法与应用
CN108250112A (zh) * 2018-01-30 2018-07-06 西北大学 一种1-烷基-1-芳硫基-2-(1h)-萘酮衍生物及其制备方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523241A (ja) * 2020-04-22 2023-06-02 アッセンブリー バイオサイエンシズ,インコーポレイテッド Hbvの処置のための5員のヘテロアリールカルボキサミド化合物
JP7830347B2 (ja) 2020-04-22 2026-03-16 アッセンブリー バイオサイエンシズ,インコーポレイテッド Hbvの処置のための5員のヘテロアリールカルボキサミド化合物
US12655130B2 (en) 2020-04-22 2026-06-16 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of HBV
JP2024539504A (ja) * 2021-10-20 2024-10-28 アセンブリー・バイオサイエンシーズ・インコーポレイテッド プロセス

Also Published As

Publication number Publication date
US20240150324A1 (en) 2024-05-09
WO2020086533A1 (en) 2020-04-30
KR20210095143A (ko) 2021-07-30
EP3870296A1 (en) 2021-09-01
US11560370B1 (en) 2023-01-24
PH12021550887A1 (en) 2022-02-21
CN113195055A (zh) 2021-07-30
BR112021007602A2 (pt) 2021-07-27
MA53983A (fr) 2021-12-15
SG11202104086PA (en) 2021-05-28
IL282433A (en) 2021-06-30
US12030869B2 (en) 2024-07-09
TW202028190A (zh) 2020-08-01
MX2021004580A (es) 2021-09-08
AU2019364352A1 (en) 2021-06-03
CA3117449A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US12030869B2 (en) 5-membered heteroaryl carboxamide compounds for treatment of HBV
JP7150903B2 (ja) B型肝炎ウイルスコアタンパク質モジュレーター
JP7759877B2 (ja) 治療用化合物
US9512122B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors
CN115843294B (zh) 用于治疗hbv的5元杂芳基甲酰胺化合物
MX2012006667A (es) Compuesto de oxadiazol novedosos.
US20220081433A1 (en) Cyclic sulfamide compounds for treatment of hbv
WO2020051320A1 (en) Cyclic sulfamide compounds for treatment of hbv
US20230295096A1 (en) Pyrazole carboxamide compounds for treatment of hbv
US20250276966A1 (en) Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives
EA053034B1 (ru) 5-членные гетероарилкарбоксамидные соединения для лечения гепатита b
WO2023069547A1 (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216661A1 (en) Pyrazole carboxamide compounds for treatment of hbv
HK40090691A (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 5-membered heteroaryl carboxamide compounds for treatment of hbv
TW202409010A (zh) 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240620